Y-Intercept (HK)’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Y-Intercept (HK)’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-18,613	Closed	-$36K	–	1357
2022 Q2	$36K	Buy	+18,613	New	+$40.6K	﹤0.01%	772

Other funds holding PRTK

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

Y-Intercept (HK)'s PRTK Position: Q3 2022 in Review

Y-Intercept (HK) sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2022, closing a stake of 18,613 shares — an estimated $36K sold.

Y-Intercept (HK) first reported a position in PRTK in Q2 2022 and held it in 1 quarter. The position peaked at $36K in Q2 2022. 72 funds tracked by Wall St. Rank hold PRTK as of Q3 2022.

Y-Intercept (HK) reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Y-Intercept (HK) sold 18,613 Paratek Pharmaceuticals, Inc. shares in Q3 2022, an estimated $36K.
Y-Intercept (HK) first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2022 and held it in 1 quarter.
Y-Intercept (HK)'s Paratek Pharmaceuticals, Inc. position peaked at $36K in Q2 2022.
72 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2022.

Based on Y-Intercept (HK)'s 13F filing for Q3 2022, filed 14 Feb 2023.